IsoRay (ISR) stock: ready for another pop?
finstead.com/bite/IsoRay-ISR-stock-forecast-prediction-august-27-2018
IsoRay is a medical company that has developed Cesium-131 as a source for radiation therapy to combat various forms of cancer. In the case of prostate cancer, the company is reviving a procedure called prostate brachytherapy, which involves placing devices containing radiation in the prostate gland close to the cancer cells.
Cesium-131 based brachytherapy solutions show a lot of promise, not only in combating prostate cancer but also in other forms of the disease. With a potential FDA approval, IsoRay has a chance to scale up; however, the company's current financial position is questionable. On July 10, IsoRay did a direct offering of 11 million common shares at $0.75 per share to institutional investors who also received warrants to purchase up to 5.5 million shares at $0.75.
IsoRay is a medical company that has developed Cesium-131 as a source for radiation therapy to combat various forms of cancer. In the case of prostate cancer, the company is reviving a procedure called prostate brachytherapy, which involves placing devices containing radiation in the prostate gland close to the cancer cells.
Cesium-131 based brachytherapy solutions show a lot of promise, not only in combating prostate cancer but also in other forms of the disease. With a potential FDA approval, IsoRay has a chance to scale up; however, the company's current financial position is questionable. On July 10, IsoRay did a direct offering of 11 million common shares at $0.75 per share to institutional investors who also received warrants to purchase up to 5.5 million shares at $0.75.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.